Worse shortness of breath; Allergic reaction; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Asthma since an unknown date. Concurrent medical conditions included Drug allergy (Percocet), Allergy to insect sting (Bee stings) and Allergy to chemicals (Industrial floor cleaner). Concomitant products included BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT RAPIHALER), TRETINOIN (ADINA), ALBUTEROL SULFATE, DULOXETINE HYDROCHLORIDE (CYMBALTA), HYDROXYCHLOROQUINE and SULFASALAZINE for an unknown indication.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Feb-2021, the patient experienced DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction). The patient was treated with PREDNISONE at an unspecified dose and frequency; ALBUTEROL SULFATE at an unspecified dose and frequency and FLUTICASONE PROPIONATE (PROAIR [FLUTICASONE PROPIONATE]) at an unspecified dose and frequency. At the time of the report, DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient has seen Pulmonologist for the reported events.    This case was linked to MOD-2021-016875 (Patient Link). This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 18-Feb-2021 and was forwarded to Moderna on 19-Feb-2021.    This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Asthma since an unknown date. Concurrent medical conditions included Drug allergy (Percocet), Allergy to insect sting (Bee stings) and Allergy to chemicals (Industrial floor cleaner). Concomitant products included BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT RAPIHALER), TRETINOIN (ADINA), ALBUTEROL SULFATE, DULOXETINE HYDROCHLORIDE (CYMBALTA), HYDROXYCHLOROQUINE and SULFASALAZINE for an unknown indication.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Feb-2021, the patient experienced DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction). The patient was treated with PREDNISONE at an unspecified dose and frequency; ALBUTEROL SULFATE at an unspecified dose and frequency and FLUTICASONE PROPIONATE (PROAIR [FLUTICASONE PROPIONATE]) at an unspecified dose and frequency. At the time of the report, DYSPNOEA (Worse shortness of breath) and HYPERSENSITIVITY (Allergic reaction) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient has seen Pulmonologist for the reported events.    This case was linked to MOD-2021-016875 (Patient Link).